Introducing Cycle Vita™
At Cycle, we know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated patient support program, which delivers individualized product support* at every step.
Enroll your patients on TASCENSO ODT® (fingolimod) to gain access to the Cycle Vita team, who have decades of experience supporting patients with MS.
Your patients will have access to individualized support* such as:
The TASCENSO Time Program
Eligible* patients will have convenient access to in-home baseline assessments (BA) and a first dose observation (FDO) as necessary to initiate their treatment. Our team have extensive experience in the management and delivery of BA and FDOs and are committed to supporting your patients during this process.
For patients switching to TASCENSO ODT from another fingolimod treatment
Patients currently taking the same dose (0.25 mg or 0.5 mg) of another fingolimod treatment a FDO will not be required, providing the patient has not had a lapse in treatment for 14 days or more.1
For patients starting on TASCENSO ODT or increasing their dose
Patients who are currently not on another fingolimod treatment or are increasing their dose (from 0.25 mg to 0.5 mg) will need to have BAs and a FDO to initiate therapy. 1
First Dose Observations
Patients will be observed for at least 6 hours after taking their first dose of TASCENSO ODT. Children will also be observed by a healthcare provider for at least 6 hours after taking their first dose of 0.5 mg of TASCENSO ODT when switching from the 0.25 mg dose.
Bridge Program
Eligible* patients who are switching to TASCENSO ODT from another fingolimod treatment will have access to our Bridge Program while Cycle Vita secures appropriate Benefit Verification and assists with Prior Authorization activities, as necessary.
It is available to patients with an urgent medical need for TASCENSO ODT, including:
- For new patients who are switching to TASCENSO ODT from another fingolimod treatment while Cycle Vita secures appropriate Benefit Verification and assists with Prior Authorization
- For existing patients who are experiencing a temporary disruption in TASCENSO ODT therapy due to changes in their insurance coverage
Financial Assistance
- Co-Pay Assistance Program - commercially insured eligible* patients may pay as little as $0
- Reimbursement Research Support – including Benefit Investigation and assistance with Prior Authorization activities, as necessary
Medication Adherence Support
- Clinical Education Managers can provide disease state and medication training to facilitate adherence
- Cycle Vita will provide relevant product information and process support to initiate treatment as soon as possible after receiving an enrollment form
Field Reimbursement
Field Reimbursement Managers (FRMs) provide regional, patient-specific support to you, your patients, and office staff, helping streamline access and reimbursement for TASCENSO ODT.
References
1. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.